linjc16/ctgov huggingface dataset:
The Epidemiological Study on Psychiatric Disorders and Psychotropic Drugs

Study Overview
=================
Brief Summary
-----------------
During the past decade, the dramatic change in patterns of both psychiatric diagnoses and prescription of psychotropic agents has been noted since the introduction of newer antidepressant drugs. In the meantime, suicide has been recognized as a major public health problem all over the world. Research efforts have hence been spent in exploring the interrelationships between suicide rates and prescription of antidepressant drugs (as a proxy for the treatment of depression). However, most available studies came from developed countries despite that the majority of countries with rising suicide rates during the past decade were developing countries. Both suicide rates and prescription of antidepressant agents have been rising in Taiwan during the past decade; with a reliable mortality registrar and nationwide health insurance covering 99% of its population, Taiwan is distinctive in realizing a large-scale analysis on these interrelationships between suicide and prescription of antidepressant drugs. However, there has been no study in Taiwan exploring these potential associations up to now. This study aims at examining the interrelationships between suicide rates and prescription of antidepressant agents based on the health insurance data from persons who had diagnoses of ICD: 290-319 or were prescribed with antidepressant agents during the period from 1998 to 2006. The investigators plan to first perform correlation analyses between the trends of suicide rates and prescription of antidepressants during the study period after taking into accounts potential confounding factors; analyses by age, gender groups and by administrative regions will also be performed. Besides, the investigators plan to analyze the change in the prescription pattern of psychotropic agents in Taiwan during the study period, with the particular focus on that of newer antidepressant drugs. The prescription of psychotropic agents in both psychiatric and non-psychiatric diagnoses will be explored.

Official Title
-----------------
The Epidemiological Study on Psychiatric Disorders and Psychotropic Drugs

Conditions
-----------------
Psychiatric Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: psychiatric disorders Exclusion Criteria: without psychiatric disorders
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prediabetes and Newly Diagnosed Diabetes in Chronic Heart Failure

Study Overview
=================
Brief Summary
-----------------
The aim the study is to determine the prevalence of prediabetic dysglycemia and newly diagnosed diabetes among individuals with CHF(chronic heart failure) in sohag university hospital patients .

Detailed Description
-----------------
- Prospective study to: study the differences in the prevalence of Prediabetes and newly diagnosed diabetes among the patients with HFrEF and HFpEF The effect of dysglycemia on prognosis of patients with chronic heart failure. The effect of early discover of diabetes mellitus on prognosis of patients with chronic heart failure

Official Title
-----------------
Prevalence of Prediabetes and Newly Diagnosed Diabetes in Patients With HFpEF( Heart Failure With Preserved Ejection Fraction) and HFrEF(Heart Failure With Reduced Ejection Fraction) in Sohag University Hospital

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Diagnostic Test: hbA1C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: All patients presented by heart failure 18 years or older Classified according to NYHA  New York Heart Association classification from NYHA class 2 and more Exclusion Criteria: Overt diabetes Rheumatic Heart Disease Congenital heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HFrEF  Heart failure with reduced ejection fraction<br>chronic heart failure with echocardiographic finding of LVEF Left ventricular ejection fraction equal or less than 40% | Diagnostic Test: hbA1C<br>* hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic<br>|
| HFmrEF Heart failure with mildly reduced ejection fraction<br>chronic heart failure with echocardiographic finding of LVEF between 41% and 49% | Diagnostic Test: hbA1C<br>* hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic<br>|
| HFpEF  Heart failure with preserved ejection fraction<br>chronic heart failure with echocardiographic finding of LVEF equal or more than 50% | Diagnostic Test: hbA1C<br>* hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart failure hospitalization. | Heart failure hospitalization or cardiovascular (CV) death, and all-cause death, and estimated hazard ratios (HR) by use of multivariable Cox regression models. | From date of randomization up to 1 month |
Vascular Disease--Structure/Function

Study Overview
=================
Brief Summary
-----------------
To investigate the relationship of non-invasively measured flow-mediated brachial artery dilation with coronary artery disease (CAD).

Detailed Description
-----------------
BACKGROUND: This study meshed with a longitudinal case-control study, HL-35333, Carotid Atherosclerosis Follow-Up Study. HL-35333 comprised 280 individuals older than 45 equally divided between men and women, half with and half without CAD evaluated for risk factors at baseline and with completed follow-up with yearly B-mode for three years. The Carotid Atherosclerosis Follow-Up Study quantified the interassociations of angiographically defined coronary artery disease and CAD risk factors with progression. The NIH funded a continuation of this effort to review existing ultrasound tapes from this study in order to additionally evaluate the associations of all these factors with extracranial carotid arterial dimensions (ECAD: interadventitial and lumen diameters) and change in ECAD over time. DESIGN NARRATIVE: The study assessed brachial artery reactivity among 100 CAD subjects and 100 controls who had been previously enrolled in a study of the relationship between extracranial intima media thickness (ECIMT) as assessed by B mode ultrasonographic measurements and CAD status. Most subjects had three consecutive B mode measurements at 12 month intervals. These subjects had brachial artery reactivity measurements according to a standardized protocol. Linear regression analysis was used to relate brachial artery reactivity to CAD status, gender and risk factors as predictors. Interaction effects were also assessed between CAD status and other risk factors and also between gender and other risk factors. Similar analyses were performed to relate percent dilation to ECIMT measurements. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Coronary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Endocrine and Nutritional Assessment in B Thalassemia Major

Study Overview
=================
Brief Summary
-----------------
B Thalassemia patients developed short stature and low weight in spite no evident endocrine abnormalities. One hypothesis is that they developed some degree of malnutrition,then the purpose of this study is to assess the nutritional status before nutritional intervention and after one year. Siblings of the patients will serve as a control group. BMI, lipid and endocrine profile and leptin levels will be analysed in the study group only.

Detailed Description
-----------------
The nutritionist will advice the patients about calories requirement and intake, balance diet and follow up the patients during the study period of one year. No special medicaments or drug therapy will be provided as part of the study protocol

Official Title
-----------------
Endocrine and Nutritional Assessment in B Thalassemia Major - A Clinical Trial

Conditions
-----------------
Thalassemia

Intervention / Treatment
-----------------
* Other: Nutritional recommendations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients above age 5 ys treated in the clinic.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Thalassemia Mayor Patients | Other: Nutritional recommendations<br>* Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI |  | 1 year study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thalassemia, Nutrition, Endocrine, BMI
Treatment of Non-Cardiac Chest Pain With Imipramine or Cognitive-Behavioral Therapy

Study Overview
=================
Brief Summary
-----------------
Approximately 75,000-150,000 patients each year in the United States undergo intensive cardiac evaluations for symptoms of angina-like chest pain that produce no positive findings. These patients often have high levels of disability and suffering and account for $250,000,000-$500,000,000 in estimated health care costs each year. There is some evidence from randomized, controlled trials that a pharmacologic agent, imipramine, and a program of training in pain coping skills and cognitive-behavioral therapy (CBT) both produce short-term reductions in pain intensity. However, no studies have compared the effects of these two treatments on measures of pain, suffering, and disability at post-treatment and over a one-year follow-up period. Our investigation is a 16-week, randomized controlled outcome study of these interventions and their respective placebo control procedures. One hundred and sixty patients are being recruited for this study. We will assess the effects of our interventions on patients' pain levels, quality of life, and health care resource usage at baseline, post-treatment, 6-month follow-up, and at 12-month follow-up. We will evaluate the clinical significance of our treatment effects as well as their statistical significance.

Official Title
-----------------
Psychophysiological Interactions in Non-Cardiac Chest Pain

Conditions
-----------------
Chest Pain

Intervention / Treatment
-----------------
* Drug: Imipramine
* Behavioral: Cognitive-behavior therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Substernal chest pain at least 2X per week for at least 3 months; Angiographic evidence of normal or non-obstructive (<50% luminal diameter narrowing) coronary arteries among subjects > 40 years of age; OR Normal exercise stress tests, normal echocardiogram, and cardiologist evaluation that symptoms are not cardiac in origin among subjects < 40 years of age; Gastroesophageal reflux disease ruled out by 24-hour pH monitoring, endoscopy, or 1-month trial of anti-reflux therapy with omeprazole 20 mg bid; Pain threshold levels for esophageal balloon distention must be 12 ml. Exclusion Criteria: Mitral valve prolapse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Imipramine|nan|
|Behavioral: Cognitive-behavior therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Imipramine, Cognitive-Behavioral Therapy
Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

Study Overview
=================
Brief Summary
-----------------
To compare the penetration of three different NSAIDs.

Conditions
-----------------
Vitrectomy

Intervention / Treatment
-----------------
* Drug: Nepafenac
* Drug: Ketorolac LS, Bromfenac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females scheduled to undergo Vitrectomy surgery Likely to complete all study visits and able to provide informed consent Visual potential of 20/25 or better Exclusion Criteria: Known contraindications to any study medication or ingredients Active ocular diseases or uncontrolled systemic disease Active ocular allergies
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nepafenac|nan|
|Drug: Ketorolac LS, Bromfenac|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinal Surgery
Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)

Study Overview
=================
Brief Summary
-----------------
The primary intention of this study is to determine the diagnostic performance of ultra-low-dose CT (ULDCT) in diagnosis and follow-up of diffuse parenchymal lung disease (DPLD). We hypothesize that inspiratory and expiratory chest ULDCT has comparable diagnostic yield to standard dose chest High-resolution computed tomography (HRCT) and utility for follow-up of patients with known DPLD. We will study this hypothesis through the following aims: Determine whether inspiratory and expiratory ULDCT are comparable to HRCT in identifying mosaic attenuation due to air-trapping. Determine whether ULDCT is as good as HRCT for follow-up of patients with established DPLD to identify disease progression.

Official Title
-----------------
Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)

Conditions
-----------------
Diffuse Parenchymal Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suspected or known DPLD referred to DPLD observation Exclusion Criteria: 1. other lung related diseases -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with suspected DPLD<br> | |
| patients with known DPLD<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome measure of this study is to determine the diagnostic performance of ULDCT in diagnosis of DPLD. | The diagnostic performance will be evaluated according to the biopsy results | during the procedure/surgery | 
| The primary outcome measure of this study is to determine the prognostic performance of ULDCT in the follow up of DPLD. | The diagnostic performance will be evaluated according to the biopsy results | during the procedure/surgery |
Incidence of Compliance to the ASA Preoperative Fasting Guidelines in Elective Surgery

Study Overview
=================
Brief Summary
-----------------
Patients scheduled for elective surgery with general anesthesia, regional anesthesia, or procedural sedation and analgesia will be interviewed about the last time having clear liquid drink light meal regular meal

Official Title
-----------------
Incidence of Compliance to the ASA Preoperative Fasting Guidelines in Elective General Surgery.

Conditions
-----------------
Compliance, Treatment

Intervention / Treatment
-----------------
* Other: Nil-per-Oral


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled for elective surgery requiring general anesthesia, regional anesthesia, or procedural sedation and analgesia. Exclusion Criteria: Patients with the order of NPO after midnight. Patients with pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients scheduled for general surgery with anesthesia<br>Patients scheduled for general surgery with anesthesia, receiving Nil-per-Oral order. | Other: Nil-per-Oral<br>* NPO details<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compliance to NPO guideline | definition of compliance include complete order of NPO for regular diet for 8 hours and soft diet for 6 hours and clear liquid for 2 hours. | 8 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Compliance, NPO guidelines
The Validity and Reliability of the Turkish Version of TASC and the Relationship Between SMC and Motor Functions

Study Overview
=================
Brief Summary
-----------------
Selective motor control (SMC) impairment in children with cerebral palsy (CP) includes movement patterns dominated by flexor or extensor synergy affecting functional movements. The research was designed to investigate the validity and the reliability of the Turkish version of the Test of Arm Selective Control (TASC) (which is improved to evaluate SMC in children with spastic CP) and in order to provide more understanding of the relationship between SMC and upper extremity and gross motor functions. The study included 21 hemiplegic, 11 diplegic and 4 quadriplegic children with CP whose ages are 4 to 18 years and Gross Motor Function Classification System (GMFCS) level changes from 1 to 4, and their parents. In order to evaluate the gross motor function of children, GMFCS and the ability to hold objects with their hands in daily activities were evaluated with Manual Ability Classification System (MACS). ABILHAND-Kids scale was applied to evaluate upper extremity performance. TASC scale was used to evaluate the upper extremity SMC of children.

Official Title
-----------------
Validity and Reliability of the Turkish Version of Test of Arm Selective Control and the Relationship Between Upper Limb Selective Motor Control and Motor Functions in Children With Cerebral Palsy

Conditions
-----------------
Cerebral Palsy, Spastic, Cerebral Palsy, Cerebral Palsy Spastic Diplegia, Cerebral Palsy Quadriplegic, Cerebral Palsy, Monoplegic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: having a diagnosis of spastic CP being able to understand the commands required for the test, being between the ages of 3-18, being GMFCS level I to IV. Exclusion Criteria: • Having undergone orthopedic surgery or Botulinum Toxin A (BTX-A) within the last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test of Arm Selective Control | an upper limb selective motor control evaluation tool. | from July to September 2018 | 
| Abilhand- Kids Questionnaire | to assess a child's unimanual and bimanual upper limb activities | from July to September 2018 | 
| Manual Ability Classification System | to assess manual abilities of children | from July to September 2018 | 
| Gross Motor Function Classification System | To assess gross motor functions of children | from July to September 2018 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cerebral palsy, selective motor control, upper limb, upper limb functions, gross motor functions